Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1034580
Abstract: Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice. As a group of European physicians experienced with burosumab… read more here.
Keywords: burosumab linked; burosumab; burosumab treatment; children adolescents ... See more keywords